1. Earlier identified differences in functional ability and radiological damage progression are maintained in the next ten years; 2. Early suppression of disease activity results in long term improvement in functional ability and suppression of…
ID
Bron
Verkorte titel
Aandoening
All patients continue treatment according to the treatment group they were allocated to at the beginning of the BeSt trial. All treatment adjustments will continue to be based on threemonthly DAS measurements, aiming at DAS =<2.4 (or <1.6 before medication may be stopped altogether).
Ondersteuning
Centocor
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Functional ability as measured by HAQ;<br>
2. Radiological damage as measured by Sharp/van der Heijde score of hands and feet;<br>
3. Side effects and extra-articular manifestations (as reported and as monitored through laboratory assessments, X-rays, DEXAs).
Achtergrond van het onderzoek
N/A
Doel van het onderzoek
1. Earlier identified differences in functional ability and radiological damage progression are maintained in the next ten years;
2. Early suppression of disease activity results in long term improvement in functional ability and suppression of joint damage progression;
3. Clinical remission can be maintained after discontinuation of all antirheumatic drugs in identifiable patients;
4. There is a clinically and statistically significant difference in extra-articular manifestations and side effects of medication between patients in the various treatment groups.
Onderzoeksproduct en/of interventie
Continued treatment with established antirheumatic drugs according to accepted treatment strategies, with threemonthly treatment adjustments dictated by the height of the DAS: if DAS>2.4, than medication will be increased or changed, if, for at least 6 months DAS <2.4, medication will be tapered, if, for at least 6 months DAS <1.6, medication will be stopped.
Publiek
Department of Rheumatology,
C1-39,
P.O. Box 9600
C.F. Allaart
Leiden 2300 RC
The Netherlands
+31 (0)71 5263598
c.f.allaart@lumc.nl
Wetenschappelijk
Department of Rheumatology,
C1-39,
P.O. Box 9600
C.F. Allaart
Leiden 2300 RC
The Netherlands
+31 (0)71 5263598
c.f.allaart@lumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
All patients who completed participation in the first 2 years of BeSt.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
N/A
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL227 |
| NTR-old | NTR265 |
| Ander register | : N/A |
| ISRCTN | Follow-up of ISRCTN32675862 |